Drug Profile

VBS 102

Alternative Names: VBS-102

Latest Information Update: 23 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VelaVigo (Shanghai) Limited
Class Bispecific antibodies; Eye disorder therapies
Mechanism of Action IGF type 1 receptor modulators; Thyrotropin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Apr 2025 VBS 102 licensed to Ollin Biosciences worldwide excluding Greater China
08 May 2024 Preclinical trials in Graves ophthalmopathy in China (Parenteral) prior to May 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com